Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Complement Component C5a

Complement Component C5a

Brief Information

Name:C5a anaphylatoxin chemotactic receptor
Target Synonym:C5AR,Complement Component 5 Receptor 1 (C5a Ligand),C5a Anaphylatoxin Chemotactic Receptor,Complement C5a Receptor 1,C5a Anaphylatoxin Receptor,C5AR1,C5a Anaphylatoxin Chemotactic Receptor 1,Complement Component 5a Receptor 1,C5a Ligand,C5A,C5R1,CD88,CD88 Antigen,Complement Component 5 Receptor 1,Receptor, Anaphylatoxin C5a,C5a-R
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Customer Reviews

Synonym Name

C5a,Complement Component 5a

Background

Human Complement Component C5a (C5a) is also known as C5,and is a protein fragment released from complement component C5.,is a potent chemotactic factor for human peripheral blood neutrophils and monocytes, and is believed to play an important role in a number of inflammatory conditions. There are several functions in the below: C5a is an anaphylatoxin, causing the release of histamine from mast cells; C5a is effective leukocyte chemoattractants, causing the accumulation of white blood cells, especially neutrophil granulocytes, at sites of complement activation; C5a activates white blood cells by increasing avidity for white blood cell integrins and upregulating the Lipoxygenase pathway for arachidonic acid metabolism; C5a is a powerful inflammatory mediator, and seems to be a key factor in the development of pathology of many inflammatory diseases involving the complement system; C5a modulates balance between activating versus inhibitory IgG Fc receptors on leukocytes, thereby enhancing autoimmune response.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Avacopan CCX-168 Approved Chemocentryx Tavneos, Vynpenta, タブネオスカプセル EU Granulomatosis with Polyangiitis; Microscopic Polyangiitis Vifor Fresenius Medical Care Renal Pharma France Vifor Sa 2021-09-27 Granulomatosis with Polyangiitis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Microscopic Polyangiitis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
TJ-210001 MOR-210; MOR044254; TJ 210; TJ210001; WBP-2191; TJ-210001; TJ-210; MOR-044254 Phase 1 Clinical Morphosys Solid tumours Details
AON-D-21 AON-D-21 Details
MP-435 MP-435 Mitsubishi Tanabe Pharma Corp Details
Avdoralimab NNC-0215-0384; IPH-5401; Anti-C5aR-215; NN-8210 Phase 2 Clinical Novo Nordisk A/S Solid tumours; Arthritis, Rheumatoid; Neoplasms; Coronavirus Infections; Pemphigoid, Bullous; Inflammation Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message